Zika Virus Program
Zika Virus Infection
Pre-clinicalActive
Key Facts
About IRBM
Founded in 1998, IRBM has established itself as a premier Italian CRO specializing in early-stage drug discovery, with capabilities spanning small molecules, AI/ML, proteomics, and functional genomics. The company operates a services-based business model, generating revenue by partnering with external clients while also developing its own internal assets. Recent milestones include a breakthrough in Zika virus drug discovery, expansion of its genomic platform, and recognition for sustainability, positioning it as a strategic partner in navigating the complex R&D pathway.
View full company profileTherapeutic Areas
Other Zika Virus Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| Zika Program | Integrated Research Associates | Pre-clinical |
| Zika Virus Vaccine Candidate | VaxSyna | Pre-clinical |